Remedium Bio
PrivateLast Round
Series A
Aug 10, 2026
Total Funding Raised
$20.72M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Remedium Bio operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series A round in September 2025.
Remedium Bio is a biotechnology company that develops gene therapies for large unmet clinical needs using its proprietary Prometheus™ adjustable gene therapy platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Remedium Bio Comparables
Compare Remedium Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Addition Therapeutics | 84% | |
| Averna Therapeutics | 79% | |
| Canary Cure Therapeutics | 79% |
For institutional investors. Book with your work email.
Remedium Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 10, 2026 | ||||
| Seed Round | May 6, 2026 | ||||
| Series A | Sep 8, 2025 | ||||
| Grant | Sep 30, 2024 | ||||
| Grant | Sep 1, 2024 | ||||
Grant | Nov 24, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Remedium Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apis Health Angels | Seed |
| Wharton Alumni Angels | Grant |
| Longevitytech.fund | Seed |
| VitaDAO | Grant |
| HKX Capital | Series A |
| Bill & Melinda Gates Foundation | Grant |
| The Bill & Melinda Gates Foundation Trust | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 44% MoM.
- Aug 17, 2026
Grew 25% QoQ, from 16 to 20 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 10, 2026
Remedium Bio, Inc. is developing durable, adjustable gene therapies for chronic disease as a preclinical-stage company, supported by the initial close of a planned $10 million Series A financing led by Lifespan Vision Ventures with participation from Eli Lilly and Company and HKX Capital in Massachusetts on Aug 10th '26.
- hiresAug 10, 2026
Remedium Bio, Inc. adds Harry Robb of Lifespan Vision Ventures to its Board of Directors in connection with the initial close of its planned $10 million Series A financing in Massachusetts on Aug 10th '26.
- is_developingAug 10, 2026
Remedium Bio, Inc. is developing durable protein therapeutics in Connecticut as of Aug 10th '26, designed to enable controlled, long-lasting therapeutic protein expression after minimally invasive subcutaneous administration.
- receives_financingAug 10, 2026
Remedium Bio, Inc. completes the initial closing of its $10M Series A financing led by Lifespan Vision Ventures, with participation from Eli Lilly and Company and HKX Capital, on Aug 10th '26 in Connecticut to advance its platform and prepare for first-in-human clinical studies.
For institutional investors. Book with your work email.
Remedium Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Remedium Bio's valuation, stock price, and market status.
Is Remedium Bio a public or private company?
Remedium Bio is a private company.
What is the current stock price of Remedium Bio?
Remedium Bio is a private company, so its shares have no public market price. Caplight tracks Remedium Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Remedium Bio worth (valuation)?
Valuation information for Remedium Bio is not publicly available.
Can I buy Remedium Bio stock?
Remedium Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Remedium Bio's last funding round?
Remedium Bio's most recent funding round was Series A on August 10, 2026.
Who are the main investors in Remedium Bio?
Key investors in Remedium Bio include Sherwood Ventures, LifeSpan Vision Ventures.
Will Remedium Bio IPO soon?
No public IPO plans have been announced for Remedium Bio.
How can I track Remedium Bio secondary market activity?
Caplight tracks bids, offers, and trades in Remedium Bio's shares on secondary markets.